Italian Journal of Dermatology and Venereology最新文献_第3页

Management of vitiligo: a promising future. 白癜风的治疗：前景广阔。

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.23736/S2784-8671.25.08112-5

Jose L López-Estebaranz, Elena García-Zamora, Joseph S Griffiths-Acha

{"title":"Management of vitiligo: a promising future.","authors":"Jose L López-Estebaranz, Elena García-Zamora, Joseph S Griffiths-Acha","doi":"10.23736/S2784-8671.25.08112-5","DOIUrl":"10.23736/S2784-8671.25.08112-5","url":null,"abstract":"Vitiligo is an autoimmune disorder marked by progressive depigmentation due to the destruction of melanocytes. Affecting 0.5-1% of the global population, vitiligo significantly impacts patients' quality of life due to its visible and psychological burden. Current treatments, such as topical agents, phototherapy, and novel immunomodulatory therapies, aim to halt depigmentation and promote repigmentation, though many patients face challenges with relapse and inadequate treatment response. A comprehensive review of literature from dermatological and immunological studies was conducted, focusing on recent advancements in topical, systemic, and physical therapies for vitiligo. Both established and emerging treatments, such as Janus kinase (JAK) inhibitors, were examined. Topical corticosteroids (TCS), calcineurin inhibitors, and novel agents like ruxolitinib have shown efficacy in managing localized vitiligo, with oral JAK inhibitors emerging as promising treatments for more extensive disease. Phototherapy, particularly narrowband UVB (NB-UVB) and excimer light devices, remains the gold standard for repigmentation, often enhanced by combining topical agents. Surgical interventions, such as melanocyte transplants, offer additional options for refractory cases, while systemic immunosuppressants and biologics require further exploration. Advances in vitiligo treatment, particularly with targeted therapies like JAK inhibitors, offer new hope for patients. However, challenges remain in achieving sustained repigmentation and preventing relapse. Future research should focus on optimizing combination therapies and exploring novel biologic agents to improve long-term outcomes.","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"248-261"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emerging role of dual specificity phosphatase 3 in melanocytic cancer: from oncogenesis to clinical value. 双特异性磷酸酶3在黑色素细胞癌中的新作用：从肿瘤发生到临床价值。

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-06-01 DOI: 10.23736/S2784-8671.25.08210-6

Emmanouil Chousakos, Nikolaos Katsoulas, Nikolaos I Vlachogiannis, Irene Theochari, Nikolaos Kavantzas, Alexandros Stratigos, Andreas C Lazaris

{"title":"The emerging role of dual specificity phosphatase 3 in melanocytic cancer: from oncogenesis to clinical value.","authors":"Emmanouil Chousakos, Nikolaos Katsoulas, Nikolaos I Vlachogiannis, Irene Theochari, Nikolaos Kavantzas, Alexandros Stratigos, Andreas C Lazaris","doi":"10.23736/S2784-8671.25.08210-6","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08210-6","url":null,"abstract":"Background: Dual specificity phosphatase 3 (DUSP3) participates in various cancers, whereas its involvement in melanocytic oncogenesis needs to be identified.Methods: One hundred seventy-two biopsied lesions were immunohistochemically stained for DUSP3, divided in 4 groups: common nevi (CN), dysplastic nevi (DN), nevus and melanoma components of nevus-associated melanomas (N-NAMs and M-NAMs, respectively). Positivity was based on the numerical and categorical Immunoreactive Score after evaluation of staining's intensity and proportion.Results: A decrease of DUSP3 positivity was observed along the 4 groups (mean [SD] numerical IRS scores: CN: 7.5 [3.5]; DN: 6.2 [3.6]; N-NAMs: 4.0 [2.9]; M-NAMs: 1.9 [1.1], P<0.001). Remarkably, no strongly positive M-NAMs were observed while 21.4% of them developed from a negative nevus. Paired analysis of the 84 matched NAM cases underscored a downgrade in positivity of M-NAM vs. N-NAM per tumor (Wilcoxon Signed-Rank Test: P<0.001). Multivariate analysis revealed that probability of any nevus diagnosis against M-NAM was increased 3-11 times (adjusted OR CN vs. M-NAM: 11.333, 95% CI: 2.995-42.876; adjusted OR DN vs. M-NAM: 6.495, 95% CI: 2.496-16.900; OR N-NAM vs. M-NAM: 3.225, 95% CI: 1.745-5.961. P<0.001).Conclusions: DUSP3 seems to act as a tumor-suppressor, and its depletion seems to contribute to the progression of NAM. This is the first study validating DUSP3's association with melanocytic neoplasms, improving the understanding of their oncogenesis and diagnostics. Additional studies are required for clarifying its utility in the clinical setting.","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"160 3","pages":"195-203"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The underestimated skin cancer risk after liver transplantation: a systematic review and meta-analysis. 肝移植后被低估的皮肤癌风险：一项系统回顾和荟萃分析。

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-06-01 Epub Date: 2025-04-02 DOI: 10.23736/S2784-8671.25.07990-3

Amr E El-Qushayri, Abdalla R Mahmoud, Abdelrahman G Tawfik, Abdullah Reda, Beatrice Nardone

{"title":"The underestimated skin cancer risk after liver transplantation: a systematic review and meta-analysis.","authors":"Amr E El-Qushayri, Abdalla R Mahmoud, Abdelrahman G Tawfik, Abdullah Reda, Beatrice Nardone","doi":"10.23736/S2784-8671.25.07990-3","DOIUrl":"10.23736/S2784-8671.25.07990-3","url":null,"abstract":"Introduction: The aim of this this systematic review and meta-analysis was to assess the prevalence of skin cancer in post-liver transplant recipients (LTRs).Evidence acquisition: Five databases were systematically searched until 20th April 2023. Search terms included (\"liver transplantation\" OR \"liver transplant\") AND (\"skin cancer\" OR \"melanoma\" OR \"squamous cell carcinoma\" OR \"non-melanoma skin cancer\" OR \"post-transplant cancer\" OR \"post transplant cancer\"). Random effect model were used to overcome the significant heterogeneity observed.Evidence synthesis: A total of 34 studies were included. The overall skin cancer prevalence in LTRs was 4.6% (95% CI: 3.4-6.1). Subgroup analysis based upon the follow-up duration of each study indicated that skin cancer prevalence increased with longer follow-up durations: 0-4 years, 0.8% (95% CI: 0.4-1.9), 4-8 years, 4.3% (95% CI: 3.1-5.8), and 8-12 years, 5.3% (95% CI: 1.9-14). Furthermore, subgroup analysis based upon continental distribution of skin cancer indicated that Australia 21% (95% CI: 13-31) followed by South America 9.4% (95% CI: 5.8-15) had the highest prevalence of skin cancer. SCC was the most common type of skin cancer with a prevalence of 2.6% (95% CI: 1.5-4.5), subsequently followed by BCC 2.5% (95% CI: 1.5-4.2).Conclusions: Skin cancer following liver transplantation is not a rare condition. Substantial dermatological surveillance programs are recommended in post-liver transplant recipients to improve the quality of life as well as the associated mortality; especially with the increased prevalence after long follow-up durations.","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"234-241"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding dermatological manifestations in carpal tunnel syndrome: a case series. 了解腕管综合征的皮肤病学表现：一个病例系列。

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-06-01 Epub Date: 2025-04-10 DOI: 10.23736/S2784-8671.25.08059-4

Michela V Starace, Stephano Cedirian, Alessio Natale, Federico Quadrelli, Yuri Merli, Giacomo Clarizio, Cosimo Misciali, Bianca M Piraccini

引用次数: 0

Scabies with acral pustules mimicking infantile acropustulosis. 疥疮与肢端脓疱模仿婴儿肢端脓疱病。

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-06-01 Epub Date: 2025-04-22 DOI: 10.23736/S2784-8671.25.08177-0

Luca Rapparini, Marco A Chessa, Iria Neri

引用次数: 0

Drug survival, long-term safety and efficacy of anti-TNF-alpha biosimilars: a monocentric retrospective study. 抗tnf - α生物仿制药的药物生存期、长期安全性和有效性：一项单中心回顾性研究

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-06-01 DOI: 10.23736/S2784-8671.25.08060-0

Giulia Nunziati, Antonella DI Cesare, Elia Rosi, Ilaria Scandagli, Gianmarco Silvi, Prisca Guerra, Francesca Prignano

{"title":"Drug survival, long-term safety and efficacy of anti-TNF-alpha biosimilars: a monocentric retrospective study.","authors":"Giulia Nunziati, Antonella DI Cesare, Elia Rosi, Ilaria Scandagli, Gianmarco Silvi, Prisca Guerra, Francesca Prignano","doi":"10.23736/S2784-8671.25.08060-0","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08060-0","url":null,"abstract":"Background: In the current landscape of psoriasis therapeutic management, despite the more recent market introduction of highly targeted molecules such as anti-interleukins, anti-tumor necrosis factor alpha (anti-TNF-α) biologic agents still play a key role, partly due to the availability of cost-effective biosimilar alternatives. Retention rate, long-term safety and effectiveness of these drugs have rarely been investigated.Methods: We carried out a retrospective monocentric study including patients treated with biosimilar adalimumab, biosimilar etanercept, and biosimilar infliximab to assess drug survival, safety and effectiveness of these drugs over an extended period.Results: A total of 93 patients were included in this study, with a median treatment duration of 86 months. Drug survival at 12 months was 91.4%, declining to <50% at 86 months. Interestingly, no significant differences were observed among the three anti-TNF-α biosimilars in terms of drug survival. The presence of psoriatic arthritis (PsA) correlated with increased drug survival. Adverse drug reactions were reported in 61.3% of patients, with infections being the most common issue. Treatment discontinuation was predominantly due to loss of efficacy.Conclusions: Despite certain limitations, such as the retrospective design and the monocentric nature of the study, our findings underscore the long-term effectiveness and safety of anti-TNF-α biosimilars in psoriasis and PsA management, emphasizing the importance of considering disease characteristics in treatment decisions.","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"160 3","pages":"204-211"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lichen striatus: a review. 纹状地衣：综述。

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-06-01 Epub Date: 2024-10-03 DOI: 10.23736/S2784-8671.24.07998-2

Astrid Herzum, Gianmaria Viglizzo, Corrado Occella, Lodovica Gariazzo, Valerio G Vellone, Silvia M Orsi, Giulia Ciccarese

{"title":"Lichen striatus: a review.","authors":"Astrid Herzum, Gianmaria Viglizzo, Corrado Occella, Lodovica Gariazzo, Valerio G Vellone, Silvia M Orsi, Giulia Ciccarese","doi":"10.23736/S2784-8671.24.07998-2","DOIUrl":"10.23736/S2784-8671.24.07998-2","url":null,"abstract":"Introduction: Lichen striatus (LS) is an acquired blaschkitis, with typical linear and unilateral distribution. It occurs mainly in children and is self-resolving, yet its etiopathogenesis remains widely unknown.Evidence acquisition: A review of the literature on LS cases was performed using the keyword \"lichen striatus\" to retrieve all relevant articles through PubMed and Google Scholar.Evidence synthesis: A total of 27 articles describing 440 LS patients were included in the present review. Mean age of patients was 3.8 years; male: female: ratio was 1:1.9. The present review confirms LS as a primarily pediatric condition, mainly affecting females. Dysregulation of the immune system might be involved in its pathogenesis, with cytotoxic T-cells attacking mosaic keratinocytes after loss of immune tolerance. The review confirms LS is mainly diagnosed clinically (80%) based on its clinical characteristics: erythematous (70%) or hypopigmented (24%) papules, distributed along the lines of Blashko. The benignity of this clinical entity is suggested by the rather short duration of disease (9.5 months on average) and by the uncommonness of therapy, adopted in only 20% of cases, and when needed, administered topically.Conclusions: This review examines the complexities of LS but acknowledges limitations in data sources and calls for further research.","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":"242-247"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Legius Syndrome: the importance of molecular differential diagnosis with neurofibromatosis type 1. Legius综合征：1型神经纤维瘤病分子鉴别诊断的重要性。

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-06-01 Epub Date: 2025-04-02 DOI: 10.23736/S2784-8671.25.08024-7

Francisco Cammarata-Scalisi, Colin E Willoughby, Antonio Cárdenas Tadich, Carmen Ludeña Mendoza, Carolina Peralta Aros, Maykol Araya Castillo, Michele Callea

引用次数: 0

Cutaneous adverse events related to skin lymphoma therapies. 与皮肤淋巴瘤治疗相关的皮肤不良事件。

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-06-01 DOI: 10.23736/S2784-8671.25.07924-1

Stephano Cedirian, Corrado Zengarini, Massimo Lepri, Bianca M Piraccini, Alessandro Pileri

引用次数: 0

Omalizumab: a broader role in dermatology? Evidence and the road ahead. Omalizumab：在皮肤病学中更广泛的作用？证据和前方的道路。

IF 1.8 4区医学

Italian Journal of Dermatology and Venereology Pub Date : 2025-05-08 DOI: 10.23736/S2784-8671.25.08144-7

Aditya K Bubna, Vinayak Viplav

{"title":"Omalizumab: a broader role in dermatology? Evidence and the road ahead.","authors":"Aditya K Bubna, Vinayak Viplav","doi":"10.23736/S2784-8671.25.08144-7","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08144-7","url":null,"abstract":"Omalizumab is a humanized monoclonal IgG1 antibody approved by the US-FDA for the treatment of chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines. The aim of this review is to outline the utility of omalizumab in all types of urticarias, as well as other off-label dermatological disorders. A comprehensive literature search was conducted to identify studies evaluating the utility of omalizumab in dermatology. Databases searched included PubMed, Medline, and Embase. All original studies including case reports, case series and clinical trials were included if they were full-text, involved a dermatologic disorder treated with omalizumab and published in English. Articles were excluded if they were conference abstracts, non-clinical reports, or invitro studies. Apart from CSU, the efficacy of omalizumab has been demonstrated in atopic dermatitis (AD), bullous pemphigoid (BP), hyper IgE syndrome (HIES), mastocytosis, and Kimura's disease (KD), with the level of evidence varying for each disorder. Besides, in anecdotal reports, the benefits of omalizumab in TEN and Netherton Syndrome has been highlighted. Omalizumab offers a promising therapeutic option for a variety of dermatologic disorders beyond CSU. Further research is needed to optimize treatment protocols and establish definitive guidelines for omalizumab use in these conditions to facilitate quicker disease remission, improved safety, and reduced reliance on conventional immunosuppressants. However, the high cost of omalizumab remains a significant barrier for its widespread use in developing countries.","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0